Medical Marijuana for Epilepsy?
Authors:
- 1 April 2016
- journal article
- Vol. 13, 23-6
Abstract
Treatment-refractory epilepsy remains an important clinical problem. There is considerable recent interest by the public and physicians in using medical marijuana or its derivatives to treat seizures. The endocannabinoid system has a role in neuronal balance and ictal control. There is clinical evidence of success in diminishing seizure frequencies with cannabis derivatives, but also documentation about exacerbating epilepsy or of no discernible effect. There are lay indications and anecdotal reports of success in attenuating the severity of epilepsy, but without solid investigational corroboration. Marijuana remains largely illegal, and may induce adverse consequences. Clinical applications are not approved, thus are restricted and only recommended in selected treatment unresponsive cases, with appropriate monitoring.Keywords
This publication has 25 references indexed in Scilit:
- Cannabis, cannabidiol, and epilepsy — From receptors to clinical responseEpilepsy & Behavior, 2014
- Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: Result of Epilepsia's surveyEpilepsia, 2014
- The case for medical marijuana in epilepsyEpilepsia, 2014
- Late onset epilepsy associated with marijuana abuse: a case report with MRI findingsPan African Medical Journal, 2014
- Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved therapeutic interventionExperimental Neurology, 2013
- The P harmacologic and C linical E ffects of M edical C annabisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Seizure exacerbation in two patients with focal epilepsy following marijuana cessationEpilepsy & Behavior, 2012
- Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic reviewBMC Neurology, 2009
- Marijuana use and epilepsyNeurology, 2004
- Pharmacology of cannabinoid CB1 and CB2 receptorsPharmacology & Therapeutics, 1997